These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 29925802)

  • 1. Possible Molecular Targets of Novel Ruthenium Complexes in Antiplatelet Therapy.
    Jayakumar T; Hsu CY; Khamrang T; Hsia CH; Hsia CW; Manubolu M; Sheu JR
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29925802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet Activity of a Newly Synthesized Novel Ruthenium (II): A Potential Role for Akt/JNK Signaling.
    Khamrang T; Hung KC; Hsia CH; Hsieh CY; Velusamy M; Jayakumar T; Sheu JR
    Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28448438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Antiplatelet Activity Relationships of Novel Ruthenium (II) Complexes: Investigation of Its Molecular Targets.
    Hsia CH; Jayakumar T; Sheu JR; Tsao SY; Velusamy M; Hsia CW; Chou DS; Chang CC; Chung CL; Khamrang T; Lin KC
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29470443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel ruthenium (II)-derived organometallic compound, TQ-6, potently inhibits platelet aggregation: Ex vivo and in vivo studies.
    Hsia CH; Velusamy M; Sheu JR; Khamrang T; Jayakumar T; Lu WJ; Lin KH; Chang CC
    Sci Rep; 2017 Aug; 7(1):9556. PubMed ID: 28842683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel iridium (III)‑derived organometallic compound for the inhibition of human platelet activation.
    Shyu KG; Velusamy M; Hsia CW; Yang CH; Hsia CH; Chou DS; Jayakumar T; Sheu JR; Li JY
    Int J Mol Med; 2018 May; 41(5):2589-2600. PubMed ID: 29436605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Therapeutic Agent against Arterial Thrombosis: An Iridium(III)-Derived Organometallic Compound.
    Hsia CW; Velusamy M; Tsao JT; Hsia CH; Chou DS; Jayakumar T; Lee LW; Li JY; Sheu JR
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29206177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of Key Antiplatelet Pathways by Bioactive Compounds with Minimal Bleeding Risk.
    Fuentes E; Wehinger S; Trostchansky A
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atractylodes lactone compounds inhibit platelet activation.
    Chen Y; Yang W; Guo L; Wu X; Zhang T; Liu J; Zhang J
    Platelets; 2017 Mar; 28(2):194-202. PubMed ID: 27560602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New thoughts on strategies for modulating platelet function through the inhibition of surface receptors.
    Nurden AT
    Haemostasis; 1996 Oct; 26 Suppl 4():78-88. PubMed ID: 8979114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy.
    Tautz L; Senis YA; Oury C; Rahmouni S
    Bioorg Med Chem; 2015 Jun; 23(12):2786-97. PubMed ID: 25921264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel antiplatelet activity of protocatechuic acid through the inhibition of high shear stress-induced platelet aggregation.
    Kim K; Bae ON; Lim KM; Noh JY; Kang S; Chung KY; Chung JH
    J Pharmacol Exp Ther; 2012 Dec; 343(3):704-11. PubMed ID: 22984226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure⁻Activity Relationship Study of Newly Synthesized Iridium-III Complexes as Potential Series for Treating Thrombotic Diseases.
    Yang CH; Hsia CW; Jayakumar T; Sheu JR; Hsia CH; Khamrang T; Chen YJ; Manubolu M; Chang Y
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30463221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current state and novel approaches of antiplatelet therapy.
    Metharom P; Berndt MC; Baker RI; Andrews RK
    Arterioscler Thromb Vasc Biol; 2015 Jun; 35(6):1327-38. PubMed ID: 25838432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genetics of antiplatelet drug resistance.
    Feher G; Feher A; Pusch G; Lupkovics G; Szapary L; Papp E
    Clin Genet; 2009 Jan; 75(1):1-18. PubMed ID: 19067731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation.
    Passacquale G; Ferro A
    Br J Clin Pharmacol; 2011 Oct; 72(4):604-18. PubMed ID: 21223359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting glycoprotein VI and the immunoreceptor tyrosine-based activation motif signaling pathway.
    Stegner D; Haining EJ; Nieswandt B
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1615-20. PubMed ID: 24925975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruthenium-conjugated chrysin analogues modulate platelet activity, thrombus formation and haemostasis with enhanced efficacy.
    Ravishankar D; Salamah M; Attina A; Pothi R; Vallance TM; Javed M; Williams HF; Alzahrani EMS; Kabova E; Vaiyapuri R; Shankland K; Gibbins J; Strohfeldt K; Greco F; Osborn HMI; Vaiyapuri S
    Sci Rep; 2017 Jul; 7(1):5738. PubMed ID: 28720875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk.
    Bae ON
    Arch Pharm Res; 2012 Oct; 35(10):1693-9. PubMed ID: 23139119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet drugs.
    De Meyer SF; Vanhoorelbeke K; Broos K; Salles II; Deckmyn H
    Br J Haematol; 2008 Aug; 142(4):515-28. PubMed ID: 18513285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of nanoscaled IQCA-TAVV as a delivery system capable of antiplatelet activation, targeting arterial thrombus and releasing IQCA.
    Wu J; Zhu H; Yang G; He J; Wang Y; Zhao S; Zhang X; Gui L; Zhao M; Peng S
    Int J Nanomedicine; 2018; 13():1139-1158. PubMed ID: 29520141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.